LID.L Share News (LID)

AIM-listed cardiovascular monitoring company LiDCO Group, has revealed that its LiDCOrapid blood monitoring system has been used successfully to monitor patients having major liver surgery. The hemodynamic system monitored cardiac output and guided intravenous fluid therapy in a randomised clinical trial on enhanced recovery versus standard care following open liver resection.The company reported that the clinical trial had involved 91 patients who were randomly allocated to receive standard care or an enhanced recovery programme (ERP) and the patients in the ERP were monitored using the LiDCOrapid system.Overall, the trial confirmed that using an ERP that included goal directed fluid therapy (GDFT) monitored by the LiDCOrapid system reduced the length of stay by three days for patients undergoing open liver resection and post-operative complications were reduced to 7.0% versus 27% in the control arm. This better care had led to "an improvement in short term quality of life for the patients in the ERP GDFT arm of the trial", the company said.LiDCOrapid uses a specific algorithm derived from the analysis of the pulse power of the arterial waveform to calculate the stroke volume from the heart. Terry O'Brien, Chief Executive Officer of LiDCO, said: "This study adds to the performance and outcomes evidence base supporting the advantages for use of the LiDCO's monitoring technology in high risk surgery patients." He added: "The ease of use of the system by healthcare professionals and benefits for patients gives us confidence that the LiDCOrapid system has the performance necessary to establish itself as the fluid monitoring system of choice in the fluid optimisation of high risk surgery patients both during and after major surgery." LiDCO Group's share price was up 10.39% to 10.62p at 11:54 on Wednesday.MF